AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors?

Epidermal growth factor receptor (EGFR) is highly expressed in triple-negative breast cancer (TNBC), and elevated levels correlate with poor prognosis. In analogy with the paradigm of oncogene addiction, blocking EGFR in TNBC was expected to have clinical efficacy – but this has not been the case. R...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Breast cancer research : BCR Ročník 15; číslo 5; s. 315
Hlavní autori: Heideman, Marinus R, Hynes, Nancy E
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 01.01.2013
Predmet:
Biomedical and Life Sciences
Biomedicine
Breast Neoplasms - metabolism
Cancer Research
Female
Humans
Oncology
Proto-Oncogene Proteins - metabolism
Receptor Protein-Tyrosine Kinases - metabolism
Receptor, Epidermal Growth Factor - metabolism
Signal Transduction
Surgical Oncology
Viewpoint
Epidermal Growth Factor Receptor Signaling
Epidermal Growth Factor Receptor
TNBC Subtype
Epidermal Growth Factor Receptor Inhibitor
TNBC Cell
ISSN:1465-542X, 1465-5411, 1465-542X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Epidermal growth factor receptor (EGFR) is highly expressed in triple-negative breast cancer (TNBC), and elevated levels correlate with poor prognosis. In analogy with the paradigm of oncogene addiction, blocking EGFR in TNBC was expected to have clinical efficacy – but this has not been the case. Reasons for these results have remained elusive. Recently, Meyer and colleagues showed interplay between EGFR and the epithelial-to-mesenchymal transition-associated AXL receptor in TNBC cells, which might provide some clues.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:1465-542X
1465-5411
1465-542X
DOI:10.1186/bcr3564